The 340B Drug Pricing Program has experienced explosive growth, leaving pharma companies struggling to understand its full impact and how it affects their market access strategies, market dynamics and contract negotiations. Pharma companies can negotiate better commercial contracts to help minimize duplicate discounts between commercial rebates and 340B. Knowing the data around your contracts can help address the ever-expanding gap between gross to net pricing and prevent revenue leakage.
Join experts as they highlight the 340B Drug Pricing Program and how the discount program is handled by commercial contracts. They’ll discuss the impact of a lack of data on revenue leakage and the importance of leveraging a data-driven solution to protect the bottom line. You’ll learn:
The impact of the 340B Drug Pricing Program on pharma companies.
How commercial contracts do (and don’t) account for 340B discounts.
The effect that incomplete data sets can have on commercial contracts.
Best practices for negotiating commercial contracts with PBMs.
How a data-driven solution can lead to more empowered negotiations.